Reason for request
Inclusion on the list of medicines approved for hospital use in the extension of the indication to the treatment of atypical haemolytic uremic syndrome (aHUS).
Clinical Benefit
| Substantial |
The actual benefit of SOLIRIS 300 mg, concentrate for solution for infusion, is substantial in this indication. |
Clinical Added Value
| important |
SOLIRIS 300 mg, an orphan medicine, provides an important improvement in actual benefit (IAB II) compared to standard treatment for patients with aHUS. |
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
gVpmLWYwJmqSnCgn
